SAN DIEGO, July 2, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced it will host an analyst/investor meeting in New York City on Wednesday, July 9, 2008. Presentations will begin at 8:00 A.M., Eastern time.
MediciNova management will provide a corporate update and overview of MediciNova's two lead product development programs: MN-166, an orally administered compound for multiple sclerosis, and MN-221, an intravenously administered compound for status asthmaticus. In addition to presentations by MediciNova management, speakers will include Dr. Andrew R. Pachner, Professor, Department of Neurology and Neurosciences at UMDNJ -- New Jersey Medical School, and Dr. Robert A. Silverman, Associate Clinical Professor of Emergency Medicine at Albert Einstein College of Medicine.
Interested parties may access a live audio webcast of the event through MediciNova's website at http://www.medicinova.com. A conference call will also be available for interested parties. To participate in this call, dial 866-272-9941 (domestic), 617-213-8895 (international), passcode: 34185117, shortly before 8:00 A.M., Eastern time. The audio webcast will be available on MediciNova's website (www.medicinova.com) for approximately 60 days following the event.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, an acute, severe asthma attack, and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit www.medicinova.com.
The MediciNova, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3135